College Receives Contract to Continue Work on Contraceptive Development
December 7, 2022
Minneapolis
The University of Minnesota has been awarded a $6.5 million contract by the Eunice Kennedy Shriver National Institute of Child Health and Human Development’s (NICHD) Contraceptive Development Program (CDP) in order to maintain its Chemical Synthesis Facility (CSF). NICHD is part of the National Institutes of Health. CDP conducts research in the synthesis and testing of a broad spectrum of male and female contraceptive agents. The ultimate goal is to develop reliable, reversible, affordable and safe contraceptive drugs available to the American public.
Media Contacts
Related Stories
Dr. Melanie Nicol, associate professor and director of graduate studies in the Department of Experimental and Clinical Pharmacology (ECP) received a new award of $3 million across the next five years from the National Institutes of Health (NIH).
Duerfeldt's research is focused on the development of chemical tools that can be utilized to enhance our understanding of disease mechanisms and the development of new therapeutic leads for bacterial infections and ocular diseases.
The Center for Drug Design (CDD), part of the University of Minnesota College of Pharmacy, created a novel technology using biomimetic decoy molecules to boost the skin's natural ability to mitigate ultraviolet-induced damage, a development that has the potential to revolutionize the skincare industry.